EuroBiotech: More Articles of Note


> NEC and Vaximm teamed up to develop personalized cancer vaccines. The project will make use of NEC’s artificial intelligence technology. Statement

> Leo Pharma exercised its option on compounds identified by HitGen. The decision marks a milestone in the relationship between the companies that began in 2015. Release

> Compugen posted initial phase 1 data on its anti-PVRIG antibody. The trial detected early signs of efficacy in microsatellite stable colorectal cancer. Statement
> Lytix Biopharma formed a clinical collaboration with Iovance Biotherapeutics. The companies will test Lytix’s oncolytic peptide in combination with Iovance’s T-cell therapy. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Poxel said FDA feedback supports its plan to use the 505(b)(2) pathway to file for approval in nonalcoholic steatohepatitis. The French biotech plans to rely on Actos data in its filing. Statement

> Lunac Therapeutics spun out of the University of Leeds with £2.7 million ($3.5 million) in series A funding. The first close of the round will support work on anticoagulants. Release 

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.